[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Eldalal et al., 2020 - Google Patents

Overview of SARS-CoV-2 Outbreak and Potential Therapeutic Strategies

Eldalal et al., 2020

View PDF
Document ID
11984459846008676989
Author
Eldalal O
Oyebanji O
Thapa P
Oroszi T
Publication year
Publication venue
Editorial Board

External Links

Snippet

The increasing severity of the ongoing COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains an urgent global issue to be addressed. Despite several heroic and concerted efforts, morbidity and mortality continue to …
Continue reading at epe.lac-bac.gc.ca (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses positive-sense
    • C12N2770/00011—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses positive-sense ssRNA Viruses positive-sense
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]

Similar Documents

Publication Publication Date Title
Wang et al. SARS-CoV-2: structure, biology, and structure-based therapeutics development
Wang et al. Coronaviruses: an updated overview of their replication and pathogenesis
Kirtipal et al. From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses
Senapati et al. Contributions of human ACE2 and TMPRSS2 in determining host–pathogen interaction of COVID-19
Poduri et al. Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19
Fung et al. Similarities and dissimilarities of COVID-19 and other coronavirus diseases
Krishnamoorthy et al. SARS-CoV, MERS-CoV, and 2019-nCoV viruses: an overview of origin, evolution, and genetic variations
Tizaoui et al. Update of the current knowledge on genetics, evolution, immunopathogenesis, and transmission for coronavirus disease 19 (COVID-19)
Ahidjo et al. Current perspective of antiviral strategies against COVID-19
Yadav et al. Emerging strategies on in silico drug development against COVID-19: challenges and opportunities
Antony et al. Role of SARS-CoV-2 and ACE2 variations in COVID-19
Ahmadi et al. Succinct review on biological and clinical aspects of Coronavirus disease 2019 (COVID-19)
Ning et al. SARS-CoV-2: origin, evolution, and targeting inhibition
Raghav et al. Human cell receptors: potential drug targets to combat COVID-19
Anastasopoulou et al. The biology of SARS-CoV-2 and the ensuing COVID-19
Ohadian Moghadam A review on currently available potential therapeutic options for COVID-19
Souza et al. The human pandemic coronaviruses on the show: The spike glycoprotein as the main actor in the coronaviruses play
Manhas et al. Covid-19 pandemic and current medical interventions
Alexandrova et al. The virus that shook the world: questions and answers about SARS-CoV-2 and COVID-19
Raj et al. COVID-19: molecular pathophysiology, genetic evolution and prospective therapeutics—a review
Xiang et al. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2)
WO2021164689A1 (en) Application of nelfinavir in preparation of drug for preventing and treating novel coronavirus pneumonia
Patil et al. Emergence, transmission, and potential therapeutic targets for the COVID-19 pandemic associated with the SARS-CoV-2
Eldalal et al. Overview of SARS-CoV-2 Outbreak and Potential Therapeutic Strategies
Kangarshahi et al. THE PROTEINS OF SARS-CoV-2 AND THEIR FUNCTIONS.